Cowie, Martin R., Cure, Sandrine, Bianic, Florence, McGuire, Alistair, Goodall, Gordon and Tavazzi, Luigi (2011) Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure, 13 (6). pp. 681-689. ISSN 1388-9842
Full text not available from this repository.Abstract
Aims A recent randomized placebo-controlled clinical trial has reported reductions in mortality and hospitalizations in patients with chronic heart failure (CHF) who were prescribed highly purified omega-3 polyunsaturated fatty acid ethyl esters (n-3 PUFA). This study aimed at evaluating the cost and benefits associated with their use in the treatment of CHF in a UK setting. Methods and results Results from a recent clinical trial were used to develop a Markov model to project clinical outcomes while capturing relevant costs and patient quality of life. The model captured outcomes over a lifetime horizon from a UK National Health Service perspective, with direct costs accounted in 2009 GBP ((sic)) and discounted at 3.5% together with clinical benefits. Results are presented in terms of life expectancy, quality-adjusted life expectancy, direct costs, and incremental cost-effectiveness ratios. In addition to standard therapy, n-3 PUFA vs. placebo increased lifetime direct costs by (sic) 993 (approximate to E1150), with additional quality-adjusted life expectancy of 0.079 quality-adjusted life years (QALYs), and mean lifetime costs of (sic)12 636 (approximate to(sic)E14 600) per QALY gained. Probabilistic sensitivity analyses suggested a 60% likelihood of n-3 PUFA being regarded as cost-effective versus placebo at a willingness-to-pay threshold of (sic)30 000 (approximate to E34 600) per QALY gained.
| Item Type: | Article |
|---|---|
| Official URL: | http://eurjhf.oxfordjournals.org/ |
| Additional Information: | © 2011 European Society of Cardiology |
| Divisions: | Social Policy LSE Health |
| Subjects: | R Medicine > RA Public aspects of medicine |
| Date Deposited: | 29 Jun 2011 14:01 |
| Last Modified: | 25 Jan 2024 21:09 |
| URI: | http://eprints.lse.ac.uk/id/eprint/37027 |
Actions (login required)
 |
View Item |
